Prabhudas Lilladher has issued a 'BUY' rating on Jupiter Life Line Hospitals with a target price of ₹360, according to their research report dated August 4, 2026. The brokerage values the stock at 26x EV/EBITDA based on FY28E EBITDA, citing the company's strong operational efficiency in competitive MMR markets and strategic expansion plans. The recommendation comes despite mixed Q1 FY27 results, with analysts expecting growth momentum to sustain over the medium term driven by scale-up in occupancy and improving margins.
Multi-speciality hospital chain operator Jupiter Life Line Hospitals Ltd reported mixed financial results for the first quarter. The company posted a net profit of ₹37.5 crore, representing a 14.6% year-on-year decline from ₹43.9 crore in the corresponding quarter last year. However, revenue demonstrated strong growth, increasing 16.4% year-on-year to ₹411 crore compared with ₹353 crore in the same period last year. The latest data from Business Standard confirms the company's revenue reached ₹410.98 crore in Q1 FY27, showing consistent growth momentum despite profitability challenges. Prabhudas Lilladher estimates Q1 consolidated EBITDA at ₹793 million, with adjusted growth at 13% YoY when excluding the Dombivli unit loss.
At the operating level, Jupiter Life showed modest improvement with EBITDA rising 1.15% to ₹79.3 crore from ₹78.4 crore a year earlier. However, EBITDA margins contracted 290 basis points to 19.3% from 22.2% in the year-ago period, indicating pressure on operational efficiency despite revenue growth. The margin compression was primarily due to the initial ramp-up loss of ₹9.5 crore at the newly commissioned Dombivli hospital and elevated marketing expenses related to its launch. Additionally, Average Revenue Per Occupied Bed (ARPOB) improved 9.21% YoY to ₹73,500, reflecting improved patient realizations and operational efficiency. Prabhudas Lilladher notes that operational efficiency has been strong in competitive MMR markets, with the company reporting revenue/EBITDA CAGR of ~20% over FY23-26.
The company announced a strategic acquisition as Jupiter Hospital Pharmacy Private Ltd (JHPPL), a subsidiary of Jupiter Life, acquired 100% equity share capital of Sulcus Private Ltd for ₹3.78 crore. Following the acquisition, Sulcus has become a wholly owned subsidiary of Jupiter Hospital Pharmacy and a step-down subsidiary of Jupiter Life Line Hospitals. Additionally, Jupiter Life appointed Harshad Purani as Chief Financial Officer (CFO) effective July 31, 2026, bringing over 20 years of experience with the company since September 2007. Purani currently serves as President Administration and Head of Corporate Social Responsibility, holding a bachelors degree in commerce and an international executive MBA from Brussels.
Dr Ankit Thakker, MD and CEO, highlighted the performance of the company's new facilities, stating that the Dombivli hospital completed its first full quarter of operations with increasing occupancy supported by growing patient footfall and expanding clinical services. The EBITDA loss from Dombivli of ₹9.5 crore in this quarter was in line with internal projections and earlier guidance. The company continues progressing with Pune South, Mira Road and BKC projects while maintaining healthy occupancy levels at established hospitals. Finance costs increased sharply by 55.5% YoY to ₹12.86 crore, reflecting borrowings undertaken to fund the company's ongoing expansion projects and the higher interest burden on the bottom line. Prabhudas Lilladher expects base business growth to pick up as occupancy and margins improve across Pune and Indore units.
According to Prabhudas Lilladher's analysis, the company's Altman Z score of 10.01 ranks it at 4th position out of 8 competitors, suggesting it may be less financially stable compared to industry peers. However, the brokerage expects 17%/10% CAGR in EBITDA/PAT over FY26-28E driven by strategic greenfield expansions in densely populated micro-markets of western regions. The company operates hospitals and clinics across Maharashtra and Madhya Pradesh, positioning itself as a leading multi-specialty healthcare provider in densely populated areas with low presence of chained hospitals. Prabhudas Lilladher maintains their 'BUY' rating with a target price of ₹360 per share, citing the company's expansion plans and improving operational metrics.
